HemaQuest Pharmaceuticals announced that the US Food and Drug Administration (FDA) has awarded the company orphan drug designations for sickle cell anaemia and beta thalassemia for HQK-1001, which is an orally administered therapeutic under clinical development for these two indications.
The details can be read here.
No comments:
Post a Comment